摘要
目的 观察盐酸埃克替尼治疗晚期非小细胞肺癌( NSCLC)的近期疗效和毒副反应.方法 回顾性分析2009年3月至2012年1月间收治的晚期NSCLC患者59例,均口服盐酸埃克替尼单药治疗,评价其近期疗效和毒副反应.全组有25例患者行表皮生长因子受体(EGFR)基因检测,其中19外显子缺失突变13例,21外显子错义突变9例,20和21外显子双突变1例,EGFR野生型2例.结果 59例NSCLC患者中,部分缓解27例(45.8％),疾病稳定17例(28.8％),疾病进展15例(25.4％),客观有效率为45.8％(27/59),疾病控制率为74.6％ (44/59).EGFR突变患者的客观有效率为73.9％ (17/23),疾病控制率为95.7％ (22/23).59例患者中,有36例(61.0％)患者在治疗后有不同程度的症状缓解,主要缓解的症状为咳嗽、喘憋、疼痛和声嘶等.治疗相关毒副反应主要为皮疹21例(35.6％),其中Ⅰ度18例,Ⅱ度2例,Ⅲ度1例；腹泻9例(15.3％),其中Ⅰ度7例,Ⅱ度2例；其他不良反应为皮肤干燥、恶心和胃部不适等.盐酸埃克替尼治疗的疗效与美国东部肿瘤协作组(ECOG)评分、治疗方式、吸烟史、EGFR突变、皮疹有关,差异有统计学意义(P＜0.05).结论 盐酸埃克替尼单药治疗晚期NSCLC近期疗效肯定,对于EGFR突变患者有效率更高,治疗相关的毒副反应较轻,患者耐受性好,为晚期NSCLC患者治疗的新选择.
Abstract
Objective To explore the efficacy and side effects of icotinib hydrochloride in the treatment of patients with advanced non-small cell lung cancer (NSCLC).Methods The efficacy and side effects of icotinib hydrochloride in treatment of 59 cases with stage Ⅳ NSCIC and followed-up from March 2009 to January 2012 were retrospectively analyzed.Results Twenty seven patients (45.8％) showed partial response (PR),17 patients (28.8％) achieved SD,and 15 (25.4％) had progressive disease.The objective response rate( ORR)was 45.8 ％ (27/59),and disease control rate( DCR )was 74.6％ (44/59).Among the 23 patients with EGFR mutation,ORR was 73.9 ％ ( 17/23 ),and DCR was 95.7％ (22/23).Thirty six patients ( 61.0％ ) achieved remission of symptoms to varying degrees.The main symptoms relieved were cough,asthmatic suffocating,pain and hoarseness.The major adverse events were mild skin rash (35.6％) and diarrhea ( 15.3％ ).Others were dry skin,nausea and stomach problems.The efficacy of icotinib hydrochloride were related to the ECOG performance status,smoking history,EGFR mutation and rash significantly ( P ＜ 0.05 ).Conclusions Monotherapy with icotinib hydrochloride is effective and tolerable for patients with advanced NSCLC,especially with EGFR mutation.
NETL
NSTL
维普
万方数据